What's in Scynexis, Inc.'s pipeline?

Scynexis, Inc. has 5 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Scynexis, Inc.'s portfolio?

Top competitors by shared drug class: Astellas Pharma Inc, Centre Hospitalier Universitaire, Amiens, Merck Sharp & Dohme LLC, Mundipharma Research Limited, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/scynexis-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Scynexis, Inc. — Portfolio Competitive Intelligence Brief

Scynexis, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
PRA	PRA	marketed	Echinocandin antifungal	β-1,3-glucan synthase (FKS)	Infectious Disease

Therapeutic area mix

Infectious Disease · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Astellas Pharma Inc · 1 shared drug class
Centre Hospitalier Universitaire, Amiens · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Mundipharma Research Limited · 1 shared drug class
Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Scynexis, Inc.:

Cite this brief

Drug Landscape (2026). Scynexis, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/scynexis-inc. Accessed 2026-05-16.